Charles Peloquin

Professor and Division Head

University of Florida

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Charles Peloquin is a Professor and Division Head at the University of Florida, USA. His research primarily focuses on pharmacokinetics and pharmacogenetics, particularly in the context of antituberculosis drugs and critical care therapeutics. Recent articles authored by Dr. Peloquin explore topics such as beta-lactam therapeutic drug monitoring, dosing strategies for tuberculosis treatments, and the interactions between HIV and tuberculosis medications.

Articles (22)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

University of Florida

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Charles Peloquin

Research Interests

Explore related searches

Contact this professor

About

Articles (22)

Impact of Timing of Beta-Lactam Therapeutic Drug Monitoring and Therapy Adjustment in Critically Ill Patients

Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial

High Time for Higher-Dose Rifampin

Linezolid Dosing and Pharmacokinetics in North American Patients With Tuberculosis

Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients

A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia

Association of piperacillin and vancomycin exposure on acute kidney injury during combination therapy

Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics

Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis

Therapeutic drug monitoring for isoniazid and rifampicin exposure

The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation

Concomitant Treatment of Tuberculosis and Hepatitis C Virus in Coinfected Patients Using Serum Drug Concentration Monitoring

Therapeutic drug monitoring in cystic fibrosis and associations with pulmonary exacerbations and lung function

Beta-lactam target attainment and associated outcomes in patients with bloodstream infections

Impact of Beta-Lactam Target Attainment on Resistance Development in Patients with Gram-Negative Infections

A Single-Run HPLC–MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant Tuberculosis

Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype

Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis

Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs

Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia

Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis

Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid

Collaborators (9)

Veena Venugopalan

Mohammad Alshaer

David Benkeser

Cesar Trillo

Lindsay Cameron

Daniel Graciaa

Charles Scanga

Kartikeya Cherabuddi

Sarah Kim

Make your next move.